AbbVie and Iambic enter AI-driven drug discovery collaboration across immunology, neuroscience and oncology
AbbVie and Iambic have entered a multi-year collaboration to use artificial intelligence and computational drug discovery across immunology, neuroscience and oncology.
The partnership will combine AbbVie's therapeutic expertise with Iambic's Enchant v3 and broader molecular-superintelligence platform to identify and optimise new small-molecule drug candidates.
Iambic will receive an upfront payment and is eligible for development and commercial milestones plus tiered royalties, although detailed financial terms were not disclosed.
Field | Content |
Alert Type | Deal |
Companies | AbbVie; Iambic Therapeutics |
Deal Type | Multi-year drug discovery collaboration |
Asset or Company | Enchant v3 and Iambic molecular-superintelligence platform |
Therapy Area(s) | Immunology; neuroscience; oncology |
Technology or Modality | Artificial intelligence; computational drug discovery; small molecules |
Deal Value | Upfront payment plus development and commercial milestones and tiered royalties; financial amounts not disclosed |
Geography | Global |
What Happened | AbbVie and Iambic entered a multi-year collaboration to apply Iambic's AI-driven discovery platform to selected targets across immunology, neuroscience and oncology. |
Why It Matters | The agreement adds another major pharmaceutical partner to Iambic's platform and reflects growing use of AI to accelerate small-molecule discovery and optimisation. |
Supporting Context | Iambic's Enchant platform is designed to integrate molecular structure, chemistry and biological data to predict properties and guide drug design. |
Strategic Rationale | AbbVie gains access to specialised AI discovery capabilities while Iambic receives funding and potential downstream economics tied to successful programmes. |
Potential Impact | The collaboration could shorten discovery cycles and expand the number of tractable targets across several high-value therapeutic areas. |
Key Takeaway | AbbVie is partnering with Iambic to apply AI-driven drug discovery across immunology, neuroscience and oncology. |
What to Watch | Selection of programme targets, candidate nominations and progression of AI-designed molecules into preclinical development. |
Primary Source | AbbVie |
Relevant Date | 21 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires